Atara Biotherapeutics (ATRA) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
The meeting was called to order by the President and CEO, with introductions of board members, executive officers, and external advisors attending virtually.
The meeting was held virtually, with voting conducted online and the session recorded for archival.
The agenda included four proposals: election of directors, advisory vote on executive compensation, frequency of future compensation votes, and ratification of the auditor.
Board and executive committee updates
Board members and key executives were introduced, including the Chair of the Board and heads of accounting, regulatory affairs, and legal.
Shareholder proposals
Four proposals were presented: election of three directors, advisory approval of executive compensation, preferred frequency of future compensation votes, and ratification of the independent auditor.
Latest events from Atara Biotherapeutics
- Registering 400,000 shares for resale by a key investor; no proceeds to the company from resale.ATRA
Registration Filing17 Mar 2026 - Returned to profitability in 2025 with a strengthened cash position and reduced expenses.ATRA
Q4 202516 Mar 2026 - Allogeneic CAR T therapies advance toward US approval and global commercialization milestones.ATRA
H.C. Wainwright 26th Annual Global Investment Conference 202414 Mar 2026 - Allogeneic T-cell therapies advance in oncology and autoimmune disease, with US launch set for 2025.ATRA
Stifel's 2024 Virtual Cell Therapy Forum3 Feb 2026 - Allogeneic T-cell platform advances with key clinical milestones and strong financial runway.ATRA
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - First-in-class allogeneic T-cell therapy advances toward U.S. approval and clinical expansion.ATRA
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - All proposals except the automatic equity plan increase were approved at the annual meeting.ATRA
AGM 20241 Feb 2026 - Allogeneic EBV T cell therapies advance in oncology and autoimmunity, with global milestones ahead.ATRA
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Allogeneic CAR-T platform advances with Tab-cel U.S. review and robust pipeline in oncology and autoimmunity.ATRA
17th Annual LD Micro Main Event Conference17 Jan 2026